Tissue Regenix Group PLC Confirmation of results
August 21 2024 - 1:00AM
RNS Non-Regulatory
RNS Number : 1644B
Tissue Regenix Group PLC
21 August 2024
Tissue Regenix Group
plc
('Tissue Regenix' or
'the Group')
Confirmation of
results
Investor presentation
Tissue Regenix (AIM: TRX), the regenerative
medical devices company, confirms that the Group's interim results
for the six months ended 30 June will be announced on Tuesday 10
September 2024.
Investor Briefing
Daniel Lee, Chief Executive Officer,
and David Cocke, Chief Financial Officer, will host a live online
presentation relating to the interim results via the Investor Meet
Company platform at 4.30pm on Tuesday 10
September 2024. The presentation is open to all existing and
potential shareholders.
Investors can sign up to Investor
Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue
Regenix on the Investor Meet Company platform will be de facto
invited.
For more
information:
|
Tissue Regenix
Group plc
|
www.tissueregenix.com
|
|
Daniel Lee, Chief Executive
Officer
David Cocke, Chief Financial Officer
|
via Walbrook
PR
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
|
Emily Watts/Geoff Nash/ Edward
Whiley - Corporate Finance
|
|
|
Nigel Birks/Harriet Ward - ECM
|
|
|
|
|
|
Walbrook PR (Financial PR and IR)
|
Tel: +44
(0)20 7933 8780
|
|
Charlotte Edgar / Alice Woodings
|
TissueRegenix@walbrookpr.com
|
|
|
|
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that
can be used to repair diseased or damaged body structures. Current
applications address many crucial clinical needs in sports
medicine, foot and ankle injuries and wound care.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRASEUFWSELSESA
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Dec 2023 to Dec 2024
